A breast cancer survivor reflects on the complicated meaning of pink, remembering what cancer took, those still fighting and the people behind the ribbon.
|Articles|November 22, 2022
Episode 31: Bladder Cancer Matters Podcast How COVID Changed How Bladder Cancer Doctors and Patients Interact with Dr. Sima Porten
Advertisement
In Episode 31 of Bladder Cancer Matters, host Rick Bangs talks with Dr. Sima Porten, a urologic cancer surgeon at the University of California San Francisco, about how COVID changed the way that bladder cancer doctors and patients interact.
Rick and Dr. Porten talk about:
- Some of the experiences of patients during the COVID-19 pandemic
- How medical distancing impacted Dr. Porten personally as well as her colleagues
- How she used telemedicine during the pandemic
- The use of in-home tests for bladder cancer that used to be done in a doctor’s office
- Disparities in bladder cancer medical care
- How COVID impacted bladder cancer clinical trial operations
Disclaimer: The views and opinions expressed in this podcast are those of the speakers and guests and do not necessarily reflect the views or positions of the Bladder Cancer Advocacy Network.
Advertisement
Related to this article
Paxalisib, first studied in brain cancer, may help HR+ breast tumors respond to CDK4/6 inhibitors again, based on early lab data.
A cancer survivor shares what to say, what not to say and how listening can help support someone through cancer treatment and beyond.
Bravnetsa is the first radioligand therapy approved through the FDA's abbreviated pathway, adding an option for adults with SSTR-positive GEP-NETs.
The investigational drug, first developed for brain cancer, is being tested to see whether it can make resistant tumors respond to treatment again.
Cancer research is increasingly looking beyond the tumor to understand the whole body, immune system and patient experience.
AI is becoming a growing part of cancer care. Learn how doctors are using it to navigate complex treatment decisions and support patients.
In patients with advanced ROS1-positive lung cancer who had not previously received a ROS1-targeted drug, Jideytro also shrank tumors that had spread to the brain in all 10 evaluable patients.
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Bravnetsa, an Equivalent to Lutathera, for GEP-NETs
2
Finding the Words: How to Talk to Someone With Cancer
3
Cancer Research Is Looking Beyond the Tumor to Better Understand the Whole Patient
4
3 More Lung Cancer Breakthroughs From WCLC 2026
5